Relief Cardiovascular, a Costa Mesa, CA-based company developing solutions for the management of heart failure, raised $12M in Series A financing.
The round was co-led by Broadview Ventures and Advent Life Sciences, with participation from Pacific Health Investment, Heartwork Capital, and an undisclosed multinational strategic.
The company intends to use the funds to support further product development and the initiation of its first-in-human feasibility study, designed to evaluate the safety and efficacy of the Relief System.
Led by CEO Alex Cooper, Relief Cardiovascular is a medical device company committed to improving outcomes for patients with heart failure. Its flagship technology, the Relief System, is a transcatheter smart implant designed to enhance fluid management and improve quality of life for heart failure patients.
As part of the financing, Shahzad Malik, MD, General Partner at Advent Life Sciences, and Maria Berkman, MD, Head of Medtech at Broadview Ventures, will join the company’s Board of Directors.
Relief Cardiovascular is an inQB8 Medical Technologies portfolio company.
FinSMEs
08/01/2025